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Incomplete understanding of the metastatic process hinders personalized therapy. Here we
report the most comprehensive whole-genome study of colorectal metastases vs. matched
primary tumors. 65% of somatic mutations originate from a common progenitor, with 15%
being tumor- and 19% metastasis-specific, implicating a higher mutation rate in metastases.
Tumor- and metastasis-specific mutations harbor elevated levels of BRCAness. We confirm
multistage progression with new components ARHGEF7/ARHGEF33. Recurrently mutated
non-coding elements include ncRNAs RP11-594N15.3, AC010091, SNHG14, 3’ UTRs of FOXP2,
DACH2, TRPM3, XKR4, ANO5, CBL, CBLB, the latter four potentially dual protagonists in
metastasis and efferocytosis-/PD-L1 mediated immunosuppression. Actionable metastasis-
specific lesions include FAT1, FGF1, BRCA2, KDR, and AKT2-, AKT3-, and PDGFRA-3’ UTRs.
Metastasis specific mutations are enriched in PI3K-Akt signaling, cell adhesion, ECM and
hepatic stellate activation genes, suggesting genetic programs for site-specific colonization.
Our results put forward hypotheses on tumor and metastasis evolution, and evidence for
metastasis-specific events relevant for personalized therapy.
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Metastasis is the leading cause of cancer-related mortalityand remains challenging due to its resistance to therapy,aggressive phenotype and multi-organ affectation1,2.
Clearly, metastasized lesions behave differently from their pre-
cursor primaries and this recognition has led to advancements of
several hypotheses, including that of cancer stem-cells to explain
this behavior3. Accordingly, attempts have been made to identify
genetic alterations that differentiate metastatic from primary
tumors4. Interestingly, most molecular comparisons have been
made between advanced primary tumors and early-stage (non-
metastasized) tumors, without looking at the metastatic lesions
themselves5,6. Very few studies have analyzed metastatic lesions
with their corresponding primaries; however, these studies were
restricted to a defined set of protein coding genes1,7. Recent
attempts using next generation sequencing have characterized the
mutational landscape of solid primary tumors to a greater detail,
but done little to add to our knowledge of metastatic disease4,8–11.
In colorectal cancer, the largest exome studies were by Giannakis
et al.12 with 619 primary tumor samples, building upon the
previous Cancer Genome Atlas (TCGA) study where 276 primary
tumors were analyzed5. A study by Yaeger et al.13 examined 1099
patients using a limited panel of up to 468 genes, but only 18
patients with matched tumor and metastasis samples, while the
study by Zie and colleagues looked into both primary colorectal
tumors and their metastases, but this study was limited to
2 samples14.
Here we present the most comprehensive analysis of whole-
genome differences between metastatic lesions and their corre-
sponding primaries in micro satellite stable colorectal cancer
samples from patients without a prior familial history of the
disease, thus reducing many hidden germline components. Using
whole-genome sequencing, we characterize the metastatic lesions
of 12 patients (details in Methods, Tables 1 and 2, Supplementary
Data 1), together with their primary tumors and corresponding
normal samples, assess somatic genomic lesions and mutational
signatures, and ascertain similarities, as well as differences
between primary tumors and metastases. Although we identify a
number of additional non-coding facets of disease progression,
more importantly, we assess and identify metastasis-specific
clinically relevant mutations and mutational signatures that may
impact future therapy decisions. The results put forward novel
hypotheses on metastasis evolution and suggest new components
of disease progression.
Results
Somatic single nucleotide variations, mutations, and indels.
First, we determined the mutational load in the 12 resected
Table 1 Patient clinical and sample information
Patient IDs Age at Surgery Gender Diagnosis Histology pT pN M Metastasis site
CRC-001 63 years 5 months Male Cancer of colon Adenocarcinoma 3 1 1 Liver
CRC-002 58 years 7 months Female Cancer of colon Tubulo-papillary Adenocarcinoma 2 1 1 Liver
CRC-003 65 years 0 months Male Cancer of rectum Adenocarcinoma 3 2 1 Liver
CRC-004 55 years 11 months Female Cancer of rectum Mildly differentiated Adenocarcinoma 3 2 1 Lung
CRC-005 48 years 6 months Male Cancer of rectum Moderately differentiated Adenocarcinoma 4 1 1 Liver
CRC-006 55 years 10 months Female Cancer of rectum Adenocarcinoma 3 2 1 Liver
CRC-007 64 years 7 months Male Cancer of rectum/colon Tubulo-papillary Adenocarcinoma 3 2 1 Liver
CRC-008 48 years 9 months Male Cancer of rectum Adenocarcinoma 3 1 1 Liver
CRC-009 70 years 5 months Male Cancer of colon Tubulo-papillary Adenocarcinoma 4 2 1 Liver
CRC-010 68 years 1 months Female Cancer of colon Moderately differentiated Adenocarcinoma 3 2 1 Liver
CRC-011 59 years 9 months Male Cancer of rectum Adenocarcinoma 3 1 1 Liver
CRC-012 62 years 9 months Male Cancer of rectum Tubulo-papillary Adenocarcinoma 3 0 1 Liver
Table displaying the anonymized/pseudonymized patient ID, age, gender, diagnosis and histology of patients/tumors. The initial staging of the disease is shown in fields for primary tumor (pT), regional
lymph nodes (pN), distant metastasis (M)
Table 2 Patient clinical and sample information, continued










Sigmoid colon (left) - 0.85 2.16 0.57 2.28
Transverse colon
(right)
- 0.55 3.28 0.56 3.33
Rectum (left) Neo-adjuvant
RCTX
0.6 3.44 below 0.3 N/A
Rectum (left) - 0.69 3.12 0.67 3.03
Rectum (left) - 0.39 3.08 0.4 2.75
Rectum (left) Neo-adjuvant
RCTX
0.36 2.19 0.63 2.21
Recto sigmoid (left) - 0.61 3.49 0.48 3.41
Rectum (left) - 0.42 3.72 0.31 3.73
Sigmoid colon (left) - below 0.3 N/A below 0.3 N/A
Caecum (right) - 0.68 2 0.65 1.73
Rectum (left) - 0.49 3.87 0.37 3.9
Rectum (left) Neo-adjuvant
RCTX
below 0.3 N/A 0.86 2.28
Tumor site and location, pre-surgical therapy, tumor cell content, tumor ploidy, metastasis cell content and metastasis ploidy are listed. RCTX abbreviates radio-chemo therapy
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metastasis samples as compared to the matched primaries (Sup-
plementary Data 2, Supplementary Figure 1). We observed a
median of 10,468 (range 5773–16,934) and 11,475 (range
4774–17,189) somatic single nucleotide variations (SNVs) in the
tumor and metastasis samples with high tumor cellularity, con-
sistent with our samples being non-hyper mutated, non-ultra-
mutated and microsatellite stable (MSS). We found that 65%
(36–92%) of all SNVs were shared between tumors and corre-
sponding metastases, clearly suggesting a common ancestral
truncal clone with 15% (1–29%) tumor-specific and 19%
metastasis-specific (3–42%), respectively (Supplementary Data 2).
This suggests that the rate of mutation is higher in the metastatic
lesion compared to the matched tumor after truncal separation.
Next, we investigated recurrent coding mutations. The most
recurrently mutated genes are well established in colorectal
carcinogenesis (Fig. 1). Mutations in these driver genes were
present in both tumor and metastasis high-purity pairs, apart
from colorectal cancer (CRC) patient CRC-010 where the TP53
mutation was only observed in the metastasis sample. In addition


























































































































































































































































































































































































Fig. 1 Recurrent somatic small mutations on protein coding genes. Oncoprint representation of recurrently mutated genes with a cutoff of 4 samples (17%).
The top annotation shows the tumor cell content (TCC) and estimated tumor ploidy. The color of the box indicates the type of mutation. Recurrently
mutated genes are marked with D, T, M if they were also recurrently mutated (>2.5%) in the Giannakis et al./DFCI 2016 (D), TCGA provision (T)
and Yaeger et al./MSK-CC 2018 cohorts (M) via cBioPortal
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guanine nucleotide exchange factor (GNEF) that facilitates small
GTPases like KRAS, and SPHKAP, which encodes an A-kinase
anchor protein.
Furthermore, we also found previously undescribed recurrently
mutated non-protein coding genes in tumors and metastases
(Supplementary Figure 2, Supplementary Data 3). These included
AC010091.1, CTD-2292P10.4, RP11-594N15.3, and SNHG14.
AC010091.1 shares homology with protocadherin FAT4, which
negatively regulates Wnt signaling and its knockdown induces
epithelial–mesenchymal transition (EMT) in gastric cancer (GC)
15. SNHG14 has been shown to bind directly to miR-145-5p16, a
potent tumor suppressor in multiple cancer types17. The non-
coding ribonucleic acid (ncRNA) RP11-421L10.1 was more
recurrently mutated in metastasis (3 vs 1).
In 3′-untranslated regions (UTRs), commonly affected genes
included XKR4, ANO5, FOXP2, CBL, CBLB, NTRK3, TRPM3,
DACH2, the latter 2 also more recurrently mutated in metastases
(3 vs 2) and FOXP2 only in diploids (Supplementary Figure 2).
We observed that 3′-UTR mutations of XKR4 were mutually
exclusive to ANO5 (i.e., patients with XKR4 3′-UTR mutations
did not harbor ANO5 3′-UTR mutations, or vice versa). These
genes are paralogs of XKR8 and ANO6/TMEM16F, which
mediate an externalization of phosphatidyl serine, creating an
immunosuppressive tumor micro environment18. Likewise,
samples with mutations in the 3′-UTR of E3 ubiquitin-protein
ligase CBL showed mutual exclusivity to its paralogue CBLB.
These genes have been shown to inhibit EGFR signaling through
degrading EGFR and binding to GRB219. CBL has also been
described to be involved in cancer progression and metastasis20,
the nuclear degradation of β-catenin21, and to downregulate PD-
L1 in non-small cell lung cancer22. FOXP2 has also been shown
to bind to and downregulate CNTNAP223. We evaluated potential
perturbations in miRNA mediated messenger RNA (mRNA)
stability caused by these 3′-UTR mutations in silico (Supplemen-
tary Data 4). In patient CRC-006, a mutation in the 3′-UTR of
FOXP2 causes the potential loss of regulation by miR-670-5p,
miR-3912-5p, miR-4669, miR-6753-3p, and miR-190b, which has
been shown to bind to the FOXP2 3′-UTR in gastric cancer (GC)
24. In CRC-004, a mutation causes the targeting of the XKR4 3′-
UTR by 7 additional miRNAs and in CRC-007, a mutation in the
3′-UTR of the same gene results in enhanced interaction of miR-
1293. Similarly, in CRC-011, a mutation in the 3′-UTR of ANO5
causes a loss of binding for 6 miRNAs; however, binding is
enhanced for 13 additional miRNAs shifting the flux towards
mRNA degradation.
Copy number aberrations. Copy number aberration (CNA)
patterns were similar in tumors and metastases (Fig. 2, Supple-
mentary Figure 3). In addition to recurrent arm level events
found in the TCGA study5, we observed recurrent amplifications
of chromosome arms 6p and q and 16p and losses in 4p, 5q, 8p.
The gains on chromosome 4 seen in tumors were virtually absent
in metastases (Fig. 2a, b). Further differences include gains of
chromosomes 9, 11 and loss of Y, which were more frequent in
metastasis samples, and gains of chromosomes 2q, 10p, 13, 17, 21
and X and losses of 15 which were less frequent.
We also observed chromothripsis-like chromosomal rearran-
gements in five samples, all of which carried a TP53 mutation.
Certain high level genomic rearrangements did not persist in the
metastasis (Fig. 3).
We also compared copy number aberrations with miRNA gene
expression changes25, and found amplifications associated with
the increased expression of miR-483, miR-409, miR-411, miR-134,
miR-154, miR-654, miR-299, miR-382, miR-379, and miR-487b in
the metastases. Deletions coupled with reduced expression were
observed for miR-34a, miR-552, miR-30e, and miR-122 in
primaries or metastases.
Structural variations. MACROD2 was the gene most recurrently
hit by structural variations (SVs), followed by PDE11A, TTC28,
FHIT, and PARK2 (Fig. 3, Supplementary Figure 4, Supplemen-
tary Figure 5, Supplementary Data 5). MACROD226, FHIT, and
PARK2 are located on chromosomal fragile sites and their dele-
tions are indicative of replication stress. Remarkably, one of the
most frequently deleted loci in the TCGA study, RBFOX1, did
not show frequent events in our cohort. The few cases (4 of 12)
where RBFOX1 showed deletions were tumor-specific events,
suggesting negative selection of RBFOX1 in metastasis. Structural
aberrations involving SAMD5, MACROD2, IGF2 and the non-
coding gene AC007319.1 were found to be more recurrent in
metastasis. SVs involving ARHGEF18, IFNGR2, RBFOX1, SLIT3,
TMEM50B, non-coding genes CTD-2374C24.1, RP11-6N13.1,
RP11-420N3.2, CTD-2207O23.3, and CTC-575N7.1 were seen
more recurrently in primary tumors (Supplementary Data 5).
An extended colorectal cancer progression model. The classical
model of colorectal cancer progression27 describes sequential
gains of mutations in Wnt signaling, RAS signaling, TGF-beta
signaling and p53 signaling. Performing mutual exclusivity and
co-occurrence analysis allowed us to place additional components
to this model (Fig. 4, Supplementary Data 6). We identified highly
redundant mutational targeting of negative regulators of the Wnt
signaling (Fig. 4a), with 85% of high-purity samples having
mutations in 3 recurrently mutated regulators. Although we
confirm known regulators, including APC, TCF7L2, FBXW7, and
SOX9 (of which the latter 3 are mutually exclusive), we show
that SOX9 is mutated in diploid only samples. This is further
supported by a significant mutual exclusivity of SOX9 mutations
with TP53 mutations (associated with aneuploidy) in the TCGA
cohort (p-value 0.025, Fisher exact test). AC010091.1, mutated
in 25% of samples, may play a role in the nuclear regulation of
β-catenin as a decoy for miRNAs targeting FAT4, a suppressor
of Wnt signaling28. Mutations in AC010091.1 were mutually
exclusive to TCF7L2 and KRAS. Our data also suggest that
LRP1B, a negative regulator of Wnt signaling that is down-
regulated in right-sided colorectal cancer (rCRC)29, may play a
role in Wnt signaling upstream of APC, as an alternative to the
TCGA’s proposed LRP5. LRP1B mutations were nearly always
associated with triploidy. Mutual exclusivity of 3′-UTR mutations
in CBL and CBLB implicate them as regulators of tumorigenic
β-catenin21 independent of FBXW7. However, CBL and CBLB
may play a dual role, as they have also been implicated in
downregulation of EGFR signaling.
We observed mutual exclusivity of KRAS, NRASmutations and
guanine nucleotide exchange factors ARHGEF33 and ARHGEF7
(Fig. 4b), suggesting that these may play a similar role to KRAS
and NRAS mutations. Other studies also showed recurrent
mutations in ARHGEF genes (Supplementary Figure 6) and the
distribution of mutations in several ARHGEF genes clustered
toward the RhoGEF and Plekstrin homology (PH) domains
(Supplementary Figure 7). In the TCGA series, we find that
ARHGEF7 mutations associate with worse disease-free survival
(p-value 0.004, logrank test) and generally, patients with ARHGEF
mutations show worse disease-free survival (p-value 0.04)
(Supplementary Figure 8). In our present series, NRAS and
ARHGEF7 were mutated only in diploid samples, while KRAS
and ARHGEF33 mutations were associated with aneuploidy and
TP53 mutations in all but 1 case.
We did not observe recurrent small mutations on components
of TGF-β signaling; however, all but one of our samples exhibited
loss of chromosome 18 which contains the key genes SMAD2 and
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SMAD4 (Fig. 4b). This loss of chr18 has also been associated with
hepatic metastasis30.
Mutations in TP53 were associated with aneuploidy (Fig. 4c).
Although most TP53 mutations were present in both tumor and
metastasis samples, CRC-010 exhibited a TP53 mutation in the
metastasis, but not the primary tumor which instead had an 11
Mb deletion spanning ATM, a regulator of TP53 (Fig. 5). This
suggested two independent carcinoma triggering events in this
patient. In line with evasion of apoptosis, we propose a potential
role of perturbed phosphatidyl serine externalization facilitating
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Fig. 2 Recurrent somatic copy number aberrations and structural variations. Relative prevalence of somatic copy number aberrations (predicted by
ACEseq) in high tumor cell content (TCC) primary tumors a and metastasis b samples, showing presence of at least one copy number gain (orange bars),
copy number loss (blue bars), and LOH (red line) as a proportion of analyzed samples. Circular plots of recurrent (minimum of 3) somatic structural
variations (SVs) in high TCC tumors c and metastasis d samples. The panels (from outside going inwards) represent small somatic variant recurrence per
gene, genomic cytobands, copy number changes (predicted by SOPHIA), and recurrent SVs within TAD regions. As an example of SV heterogeneity, we
show the SV landscape for CRC-005 tumor e and metastasis f. Arcs represent translocation and inversion events
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immune evasion, by dysregulating 3′-UTR mutations of the
XKR and TMEM16 family genes XKR4 (exclusively mutated in
triploids) and ANO5 (TMEM16E). Recently, it has been shown
that both CBL and CBLB play a role in modulating expression of
programmed death ligand 1 (PD-L1), thus also playing a role in
immune evasion (Fig. 4c).
Finally, by stratification of the mutational catalog, we were able
to identify signatures particular to early-stage development
(Fig. 6), and later evolution of the resultant tumor and metastasis
samples. We observed more prominent DNA mismatch repair
(MMR) defect signatures (AC6 and AC15) in early development,
which seemed to be replaced by gain of a DNA, double-strand
break-repair by homologous recombination (DSB) repair defec-
tive signature (AC3) in later stages (see following section).
Mutational patterns and signatures in disease progression. We
sought to identify additional patterns that would potentially be
indicative of disease progression after finding evidence for an
increased mutational rate in metastases as compared to primaries.
Looking into cancer mutational signatures31 of the stratified
catalog of tumor-specific, metastasis-specific, and shared muta-
tions, we found signatures AC1, AC3, AC5, AC6 and AC9, AC10,
AC13, AC15 and AC17 (Fig. 6a, b). Signatures AC1 and AC5 are
believed to be caused by age-related clock-like mutagenic pro-
cesses, AC1 initiated by spontaneous deamination and AC5 by an
unknown mechanism. Signatures AC3, AC6, and AC15 have
been associated with failure of DNA repair systems, in case of
AC3 by failure of double-strand break-repair by homologous
recombination and in case of AC6 and AC15 by failure of mis-
match repair (MMR); signature AC9 is attributed to the activity
of activation-induced (Cytidine) deaminase (AID). Signature
AC10 has been linked to altered polymerase (POL) E function,
signature AC13 is linked to the activity of members of the
APOBEC enzyme family and signature AC17 has not been
associated with a specific mechanism yet.
Unsupervised clustering of the stratified catalogs based on
normalized exposures of mutational signatures revealed a
significant association between ploidy and the clock-like signa-
tures AC1 and AC5: high exposure to AC1 is associated with
polyploidy, whereas enrichment of AC5 is associated with
diploidy (Fig. 6c).
Comparing normalized exposures in different strata of SNVs,
the clock-like signature AC1 (spontaneous deamination) is more
truncal (significant before, trend after Benjamini-Hochberg (BH)-
correction). Furthermore, we observed differences in DNA repair
defect signatures: AC6 and AC15 (MMR) are truncal (significant
before, trend after BH-correction), whereas AC3 (DSB, BRCA-
ness) is an ongoing mutational process with significantly higher
contributions in the strata private to tumors and metastases
(Fig. 6d). This again supports the hypothesis of a common
ancestor clone between tumor and metastasis with altered late
stage mutagenic processes ongoing after truncal separation.
Functional relevance of metastasis-specific mutations. We
found 48 genes to be mutated in metastases but less so in primary
tumors. Performing functional annotation clustering analysis, we
found extracellular matrix, PI3K-Akt signaling, and focal
adhesion-related pathways to be significantly enriched in metas-
tases (p-value of 1.2 × 10−11, 2.7 × 10−10, and 2.2 × 10−5,
respectively; BH corrected hypergeometric test; Supplementary
Figure 9, Supplementary Data 7). Of these 48 genes, 12 were
present in the matrisome of metastatic CRC tumor samples of
which 11 had lower protein abundance in the metastasis sam-
ples32, including ADAMTSL1, which was a colon tumor-specific
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Fig. 3 Chromothripsis and negative selection of highly rearranged chromosomes. Chromosome copy number predictions of six samples a–f, showing
predicted copy number of tumor (top) and metastasis (bottom) samples. Regions of chromothripsis-like rearrangements b, c, f and highly rearranged
events not present in the metastasis a, d, e, f are highlighted in dashed red boxes
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metastasis nor liver tissue. None of the metastasis-specific ECM
proteins were found in the list of 48 mutated genes.
Additionally, looking at canonical pathways enriched either in
tumor or metastasis specifically mutated genes, we found that
hepatic fibrosis/stellate cell and actin cytoskeleton cascades were
significantly enriched in metastasis (Supplementary Figure 9). As
almost all our sequenced metastatic lesions were in the liver, it
appears that metastasized cells invoke a response that in some
way fosters organ-specific metastatic colonization.
Clinical relevance of metastasis-specific mutations. Genomic
alterations in the metastasis genome are clinically relevant if they
are actionable (for therapy or decision-making) and more so if
they differ from that of the primary tumor. To analytically eval-
uate such alterations, we used the TARGET database as well as the
database of the NCT-MASTER program33 to ascertain potentially
clinically relevant events in the tumor and metastasis tissues for
individual patients. The number of these mutations in the indi-
vidual patients ranged from 1 to 17, with an average of nine
mutations per sample. Most clinically relevant mutations were
identical between tumor and metastasis samples from the same
patients. However, in four patients, we found clinically relevant
metastasis-specific non-silent mutations of FAT1, FGF1, BRCA2,
TP53, and KDR and tumor-specific splice site mutations of JAK2
(Supplementary Data 8). We also searched for alterations in the
3′-UTRs of potentially targetable genes and discovered, with the
exception of two patients, at least one per patient affecting
different genes. Interestingly, three patients harbored 3′-UTR
mutations in genes of clinical interest: AKT3 (CRC-002), PDGFRA
(CRC-005), and AKT2 (CRC-010) (Supplementary Data 9).
We also observed EGFR amplifications in the metastasis
sample of CRC-005 (4 copies) compared to the tumor (3 copies),
implicating consequences for EGFR-based targeted therapy of
certain metastases.
Finally, we observed a significantly reduced defective DNA
mismatch repair signature (AC3) in the tumor and metastasis-
specific mutations compared to the truncal node, but persistence
of BRCA-ness mutational signatures, suggesting possible efficacy
of PARP inhibitor treatment for both the primary tumors and
metastases. An overview of our findings and suggestion of an
extended progression model of colorectal cancer and its
metastasis is shown in Fig. 7.
Discussion
This is the most comprehensive study to date systematically
describing whole-genome landscape differences in tumor and
metastatic lesions of colorectal cancer. In our study, an average of
65% of all somatic SNVs were shared between tumors and cor-
responding metastases; an average of 15% were specific to tumors
and an average of 19% specific for metastases, suggesting that the
rate of mutagenesis is higher in the metastatic clone compared to
the primary tumor.
In line with the Vogelstein model27, we revealed additional


























































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 Pathway model of colorectal cancer molecular drivers. Cartoon model (top) and oncoprints (bottom) of somatically mutated genes within colorectal
progression pathways. Models and oncoprints of recurrently mutated genes within β-catenin/Wnt a, growth factor & RAS b, and apoptosis signaling
c pathways. Genes were identified based on mutual exclusivity analysis and literature. Genes identified to be mutated in this study are shown in green ovals
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dependency of existing mechanisms to ploidy state. Thus, the
model can now be further refined34. The initial lesion for non-
hyper mutated/microsatellite stable tumors is adenoma genesis
via redundant perturbations in Wnt signaling leading to over
expression of β-catenin for which we identified components
LRP1B, AC010091.2, CBL, and CBLB. We hypothesize that the
guanine nucleotide exchange factors ARHGEF33 and ARHGEF7
may play a similar role to KRAS and NRAS mutations. While
these ARHGEF genes were identified in our series, we found a
number of other ARHGEFs that exhibited clustered and recurrent
mutations on functional domains, further implicating an
important and yet unexplored role of ARHGEF genes. This is of
special importance as patients with KRAS and NRAS mutations
do not respond well to EGFR inhibitors panitumumab and
cetuximab35, which may mean that patient CRC-005 that
exhibited an EGFR amplification in the metastasis but also carried
an ARHGEF33 mutation, may not respond to EGFR inhibitor
therapy. While the role in TP53 in carcinoma formation is well
known, we postulate the role of perturbed phosphatidyl serine
externalization interfering with efferocytosis as a result of
potential dysregulation of XKR4 and ANO5 by 3′-UTR muta-
tions, which we believe work co-operatively with TP53 mutations.
The clock-like signature AC1, scaling with the number of
passed cell cycles36, is enriched in polyploid samples, whereas
signature AC5, scaling with elapsed time, is enriched in the
diploid samples. A possible interpretation is that rapidly cycling
tumors are more prone to be associated with gross karyotypic
abnormalities. This could stratify patients into clinical subgroups
of better responders to drugs with strong anti-proliferative
activity, such as 5-fluorouracil (5-FU). Defective DNA DSB
repair machinery as indicated by mutational signature AC3 can
be targeted by PARP inhibitors. PARP inhibitors could be
used not only as chemo/radiotherapy sensitizers, but as single
agents to selectively kill cancers defective in DNA DSB repair
while overcoming typical resistance of MMR defective tumors
to chemotherapy37.
The clinically relevant genes that we found which were
exclusive to metastatic lesions include FAT atypical cadherin 1
(FAT1), which regulates cell adhesion, migration, EMT and
stemness properties. Somatic mutations of FAT1 have been found
to lead to aberrant Wnt activation in multiple human cancers38.
FAT1 is widely expressed in metastatic CRC and can be targeted
directly with monoclonal antibody mAb198.339. Fibroblast
growth factor 1 (FGF1) is targetable indirectly through its
receptors, FGFRs, with agents, including Nintedanib, Pazopanib,
Ponatinib40. The Kinase insert domain receptor (KDR/VEGFR),
functions as the main mediator of VEGF-induced proliferation,
survival, migration, and sprouting, and is amenable to drugs,
including axitinib, sorafenib, and cabozantinib41.
We identified recurrent chromosome arm level events and
highlight differences between tumor and metastasis samples.
There is an evidence that loss of chromosome 4 is associated
with lymph node metastasis, metastatic recurrence, and early
micrometastasis42,43. Similar reporting of chromosome 4 ampli-
fications in primary tumors but not their matched metastases has
been described for metastatic melanomas44, which was localized
to 4q12-q13.1 which includes PDGFRA, KIT, KDR, and REST.
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Fig. 5 Genomic landscape of tumor and metastasis mutations in patient CRC-010. Model of progression of tumor and metastasis from normal epithelial
cells a, mutational signatures for tumor (dark blue), shared (red), and metastasis (dark red)-specific mutations b, structural variations in tumor c and
metastasis d and copy number profiles in tumor e and metastasis f. ATM is located in the small deleted segment of chromosome 11 in the tumor sample d
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by driving EMT and proliferation45,46. KIT and REST have been
implicated as tumor and metastasis suppressors in colorectal
cancer47,48. Perhaps, this schizophrenic region drives hetero-
geneity where amplification increases proliferation while reducing
its metastatic potential, whereas deletions lead to lower levels of
KIT and REST, thus more viable to metastasize.
Importantly, facilitated by whole-genome sequencing, non-
coding genes and 3′-UTRs provided significant contributions
to the better known protein-coding mutational landscapes of
CRCs49–51. At present, it is difficult to completely appreciate their
impact as their functions are still poorly understood. Certainly, in
an earlier publication, we have described the metastasis-specific
microRNA landscape and many of the genomic changes are
able to offer putative explanations for particular miRs we have
described to be deregulated in expression in metastasis25. We
observed metastasis-specific 3′-UTR mutations in AKT2 and
AKT3. Furthermore, in our study, there is an indication of the
importance of 3′-UTR mutations in CBL and CBLB, which plays
multiple roles including degradation of tumorigenic β-catenin
(encoded by the CTNNB1 gene) in colorectal cancer21, degrada-
tion of EGFR19, and suppressing the expression of PD-L122. We
also observed that the most frequent 3′-UTR mutation, which
occurred in XKR4, was exclusively in triploid samples, and
exhibited mutual exclusivity to 3′-UTR mutations in ANO5,
potentially interfering with efferocytosis. Mutations for both
these genes facilitated binding of additional miRNAs in silico18.
Together, the potential combined effect of modulation of mac-
rophages via efferocytosis and T-cells via PD-L1 expression,
prime a favorable tumor-microenvironment raising the impor-
tance of dysregulation of CBL, CBLB, XKR4 and ANO5 in col-
orectal carcinoma.
Another highlight is the finding that metastatic lesions are
enriched in mutations of genes affecting PI3K-Akt signaling, cell
adhesion, extracellular matrix, and stellate-cell activation in the
liver, the predominant metastasis site in our patient, which we
hypothesize is critical for homing within the metastatic niche.
This supports the notion that sporadic genetic changes are
priming metastatic colonization of tumors to a specific metastatic
site, and this is perhaps where the fundamental differences
between tumors and metastases lie. Extensive investigations are
needed to evaluate functionality of these hypotheses.
Taken together, metastases and tumor genome landscapes are
very similar, but definitely not identical, which supports the
hypothesis of a divergent evolution of metastatic lesions as com-
pared to the primary tumor after truncal separation. While most
of our samples support a late dissemination model, the indepen-
dent carcinoma triggering events in patient CRC-010 would argue
for an early metastasis model52, with the split occurring after the
intermediate adenoma. In individual cases, actionable mutations
private to metastatic lesions are evident. This clearly may warrant
clinical consequences and a re-structuration of current persona-



























































































































































































































































































































































































































































































































































































































Fig. 6 Mutational signatures in colorectal cancer progression. Bar plot representation of absolute a, and normalized b COSMIC cancer mutational
signatures within the strata of tumor-specific (dark blue), metastasis-specific (dark red) and shared (purple) somatic SNVs per patient with high tumor cell
content (TCC). Unsupervised clustering of normalized exposures, with top annotation showing ploidy, estimated TCC and mutational status for TP53,
KRAS, ARHGEF33, TCF7L2, and FBXW7 c. Box and whisker plot of distributions of normalized exposures between mutations that are tumor-specific (dark
blue), metastasis-specific (dark red), and shared (purple) per patient d. Boxes denote the interquartile range, the middle line denotes the median, and the
vertical lines outside the box denote the minimal and maximum range excluding outliers (which are 1.5 times the interquartile range)
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Fig. 7 Model of colorectal cancer and metastasis progression and therapeutic implications. A summary cartoon of how recurrent somatic mutations
identified within this study fit into established colorectal progression models a. The top cartoons represent the transition from normal epithelial cells to
metastasis (left to right). Beneath the cartoons are tables of genes and genetic lesions that were mutated in our cohort, sorted in tables related to possible
pathway function. Change of relative exposure to mutational signatures are shown as horizontal bars where the strength of exposure corresponds to the
strength of color in the bar, relative to tumor evolution (left to right) b. Cartoon representation of lesion (stars) accumulation giving rise to tumor
heterogeneity c. Balloons are colored according to pathways, as the table headers in a, showing mutations in Wnt (green), RAS (orange), TGF-β (blue)
signaling, and mutations acquired in carcinogenesis (brown), and metastasis (dark brown) formation. We show events which might not give rise to further
progression. Mutations with implications on therapy decision are shown in light blue boxes with rounded corners, and linked to boxes with therapy
consideration via a thick black line a, b. Gray vertical dashed lines separate out lesions corresponding to truncal origin, tumor, and metastasis states
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Methods
Patient material. Primary tumor, matched metastases and corresponding normal
tissues of 12 patients with colorectal cancer were obtained at the Medical Faculty
Mannheim, University of Heidelberg, Germany (Tables 1 and 2). The tissue
banking and sample study was approved by the Ethical Committee of the Uni-
versity Hospital Mannheim, Medical Faculty Mannheim of Heidelberg University,
all relevant ethical regulations were complied with, and informed consent was
obtained from all patients or their spouses/relatives when the former were
deceased. Bio banking and handling of the tissues followed the BRISQ guidelines53.
Genomic DNA isolation. Genomic DNA was isolated from 5 to 10, 20 μM cryo-
section slices (depending on tissue size) using the QIAamp DNA mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s manual. The extracted DNA
was submitted to the HIPO Sample Processing Laboratory (HIPO-SPL) for quality
check and pseudo-anonymization of the samples, then transferred to the Genomics
and Proteomics Core Facility of the German Cancer Research Center for
sequencing.
Whole-genome sequencing and alignment. Whole-genome DNA sequencing
was performed on the HiSeq2000 platform. Library preparation and whole-genome
sequencing of matched tumor/normal/metastasis DNA was carried out54. Briefly,
1–5 μg of genomic DNA was fragmented to ~300 bp and size selection conducted
by agarose gel excision. Sequencing reads were mapped and aligned using the
DKFZ alignment workflow from ICGC Pan-Cancer Analysis of Whole Genome
projects [https://dockstore.org/containers/quay.io/pancancer/pcawg-bwa-mem-
workflow]. Read pairs were mapped to the 1000 Genomes Project phase 2 assembly
of the human reference genome (hs37d5) using Burrows-Wheeler Aligner soft-
ware55 (version 0.6.2) using default parameters apart from -T 0. Duplicates were
marked with biobambam (version 0.0.148). Single nucleotide variants and indels
(insertion or deletion) of the most significant findings were validated by poly-
merase chain reaction (PCR) using primers that flanked the mutated sequence.
Sanger sequencing was done followed by comparisons to the germline genome
sequence for confirmation.
Small variant calling. Small variants were called from the whole aligned whole-
genome sequencing data. They were initially called using our in-house workflows,
described below, followed by cross checking of variant positions between tumor
and metastasis pairs. SNVs were initially called using the DKFZ SNV and indel
calling workflow from ICGC Pan-Cancer Analysis of Whole Genome projects
[https://dockstore.org/containers/quay.io/pancancer/pcawg-dkfz-workflow]54,56.
Briefly, the SNVs were called using samtools and bcftools version 0.1.1957 deter-
mined to be somatic or germline by comparing the tumor/metastasis sample to the
control, and later assigned a confidence. The confidence score was initially set to
10, and subsequently reduced based on overlaps with repeats, DAC blacklisted
regions, DUKE excluded regions, self-chain regions, segmental duplication records
as introduced by the ENCODE project58 and additionally if the SNV exhibited PCR
or sequencing strand bias. SNVs with confidence lower than 8 were excluded.
Annovar (release Feb 2016)59 using gene models from Gencode version 19 were
used to annotate SNVs.
Due to potential tumor in normal contamination leading to false negative calls
we applied the TiNDA (tumor in normal detection algorithm) workflow
(unpublished). Briefly, using the unique set of combined mutated positions for a
tumor metastasis pair the B-allele frequency (BAF) was calculated from the tumor,
metastasis and control samples. Positions overlapping with common variants were
filtered out. Then, the clustering algorithm from Canopy60 was applied to the BAF
values for the positions in tumor/metastasis vs the control using a single pass run,
assuming 9 clusters. The clusters that were determined to be tumor-in-normal had
to have 75% of positions above the identity line, the tumor/metastasis mutant allele
fraction (MAF) above 1% and the control MAF below 45%. These identified
mutations were then reclassified as somatic instead of the original germline
annotation.
Indels were initially called using Platypus61 version 0.8.4. Platypus filters were
used to calculate a confidence score ranging from 0 to 10. Indels with confidence
lower than 8 were excluded. Annovar was used to annotate indels.
Due to varying tumor cell content, we cross checked allele frequencies of
mutations between tumors and metastasis to validate those small mutations were
not missed due to lower tumor cell content in either the tumor or metastasis
samples. A SNV was called when (i) it was called somatic using our in-house
workflow, (ii) it was called somatic in the matched tumor/metastasis pair and its
MAF was above 5% (corresponding to a minimum of 2 reads) and at least twice
that of the matched germline control. This threshold of 2 reads was selected based
on our series (i) where some of the samples are triploid (median series ploidy) (ii)
with ×36 coverage (median series coverage), (iii) and with a tumor purity of 47.5%
(median series purity), where the expected read support for a single copy variant
would be 5.7 reads (0.475 × 36/3). Using a Poisson distribution model, variants
with 2 read support fall within the majority of the distributions (pPoisson (X= 2)
= 0.54, where μ= 5.7). SNVs that were shared between tumor and metastasis
samples tended to have similar variant allele fractions (VAF) (Supplementary
Figure 1). In some samples (CRC-004, CRC-006, and CRC-007) we observed
slightly lower VAF in the tumor- and metastasis-specific mutations compared to
the shared mutations, indicating a dominant truncal clone with low level
heterogeneity.
We classify mutations of interest as somatic SNV and indels those causing
protein coding changes (non-silent), and also exonic mutations on non-coding
genes. Annotation of non-silent mutations in protein coding genes include non-
synonymous SNVs, gain or loss of stop codons, splice site mutations, and both
frameshift and non-frameshift indels in protein coding genes for mutations of
interest on non-coding genes we used all exonic and splicing mutations.
A total of 2403 mutations of interest were detected, of which 1589 were in
protein-coding genes and 814 in non-coding genes (Supplementary Data 10). The
average number of mutations of interest per sample was 200 (range 94–351), of
which an average of 132 (range 73–222) were in protein-coding genes, and 78 were
in non-coding genes (range 21–129). These alterations hit 1428 protein-coding and
764 non-coding genes, of which 145 and 61 were hit in 2 or more samples,
respectively (Supplementary Data 10). Relative to SNVs, much fewer indels were
called, with the average per sample was 15 (range 8–23), of which an average of 7
(range 2–18) were in protein-coding genes, and 8 were in non-coding genes (range
4–14). These alterations hit 74 protein-coding and 94 non-coding genes, of which 3
and 1 were hit in two or more samples, respectively (Supplementary Data 11).
Among the most recurrently mutated genes, APC was mutated in all high-
purity samples and TP53 in 15 samples. Further recurrently mutated genes
included KRAS, NRAS, SOX9, TCF7L2, and FBXW7. We observed mutations in
TTN and LRP1B which have been described as passenger mutations, although
LRP1B is a paralogue of LRP1, which is known to be involved in Wnt receptor
signaling. SOX9 was exclusively hit by frameshift insertions and deletions and
always co-occurred with mutations in HK3, but this was not observed in the larger
TCGA and Giannakis cohorts.
Correlating these recurrently mutated protein coding genes, ncRNAs and 3′-
UTRs with clinical factors we found that KRAS was mutated exclusively in right
sided colon and caecum tumors (compared to left sided sigmoid) and TP53 was
mutated only in left sided sigmoid (compared to right sided colon and caecum)
(Supplementary Data 12) consistent with observations by Yaeger et al.
Additionally, we found mutations in RP11-983P16.2, POKR1, SLC26A10 affect
females more than males (p 0.0455, χ2-test), 3′-UTRs mutations of CBLB, IFI44L,
MMP16, RNF217 affect females more than males (p 0.0455, χ2-test), and 3′-UTR
mutations of XKR4 were found 3 of 3 patients who did not undergo neoadjuvant
therapy (compared to 0 of 3 who did).
The mean inter-mutation distance across the genome was between 10,000 and
1,000,000 bp and we did not observe recurrent regions of kataegis in our patients.
Some of these individual kataegis loci were in close proximity to genes PEAK1,
ADAP2, SUFU, and SGK3, with SUFU being metastasis-specific and SGK3 tumor-
specific (Supplementary Figure 10, 11). However, several recurrent regions of
increased mutation density were seen in both tumor and metastases, most
prominently on chromosomes 5 and 13 which may be due to a gain of partially
methylated domains62 (Supplementary Figure 10, Supplementary Figure 11).
Sample classification. The samples in our series were all deemed to be micro-
satellite stable; they did not harbor mutations on DNA mismatch repair genes
MLH1, MLH3, MSH2, MSH3, MSH6, PMS2 suggesting that they were not micro-
satellite instable/hypermutators, nor did they harbor mutations on POLE sug-
gesting that they were neither ultra-mutators.
The sample exhibiting the most mutations in our series (CRC-008, primary
tumor) has 17,189 somatic SNVs, equivalent to 6.1 mutations per 106 bases
(assuming 2.8 Gb of mappable human genome), which is about half of this
hypermutator boundary. By extension, our samples cannot be classified as ultra-
mutators.
Mutual exclusivity analysis. Mutual exclusivity analysis was initially performed
on all genes that have established roles in colorectal cancer. Gene pairs were
deemed to be mutually exclusive if no more than 1 sample harbored somatic SNVs
for them. Using cBioPortal, we determined the significance of mutual exclusivity
and co-occurrence of recurrently mutated genes in our, the TCGA, Giannakis et al.,
and Yaeger et al. studies, and the ARHGEF gene family (Supplementary Data 7).
We found support to our observation of mutual exclusivity of ARHGEF7-KRAS
(TCGA, p-value 0.021, Fisher test) and SOX9-TP53 (Yaeger et al., p-value <0.001),
NRAS-KRAS (Yaeger et al., p-value <0.001). We found SOX9 mutations co-
occurred with HK3 mutations, and with frameshift indels in APC as opposed to
typical stop gains, although we did not observe co-occurrence of SOX9 and HK3 in
larger cohorts.
Survival analysis. Survival analysis (overall and disease-free) was performed using
cBioPortal on the TCGA provisional dataset using ARHGEF7 and all ARHGEFs
combined: ARHGEF1, ARHGEF10, ARHGEF10L, ARHGEF11, ARHGEF12, ARH-
GEF15, ARHGEF16, ARHGEF17, ARHGEF18, ARHGEF19, ARHGEF2, ARH-
GEF25, ARHGEF26, ARHGEF3, ARHGEF33, ARHGEF34P, ARHGEF35,
ARHGEF37, ARHGEF38, ARHGEF4, ARHGEF40, ARHGEF5, ARHGEF6, ARH-
GEF7 and ARHGEF9 (Supplementary Figure 8).
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Structural variant calling. Structural variations (SV) were called using the
SOPHIA algorithm (manuscript in preparation) using a workflow as described in
Sahm et al.63.
Briefly, SOPHIA uses information of supplementary alignments from the
alignment file as produced by bwa-mem. This indicates candidate chimeric
alignments of split-reads which would be an indication of a possible underlying SV.
SOPHIA uses a decision tree to consider only high-quality reads that do not fall on
lowly mappable regions or consist of low-quality base calls. SOPHIA uses these
reads and further filters the results by comparing them to a background control set
of sequencing data derived from normal blood samples from a large background
population database of 3261 patients from published TCGA studies and both
published and unpublished DKFZ studies, sequenced using Illumina HiSeq 2000,
2500 (100 bp) and HiSeq X (151 bp) platforms and aligned uniformly. A SV is
discarded if: it has more than 75% of read support is from low-quality reads; the
second breakpoint of the SV was unmappable in the sample and in 10 or more
background control samples; a SV with 2 breakpoints had one present in at least 98
control samples (3% of the control samples); both breakpoints have less than 5%
read support at both positions.
In addition to the recurrently hit genes, we also found a number of topologically
associated domains that were recurrently hit by SVs, including
chr10:13,280,000–15,440,000 (containing SUV39H2), chr1:3,360,000–3,359,999
(MUM1, GNA15, GNA11, STK11, and TCF3), chr14:67,880,000–69,720,000
(RAD51B), and chr19:14,600,000–16,800,000 (BRD4) (Supplementary Data 13).
Copy number aberration calling. Copy number aberrations (CNAs) were called
using ACEseq64, which is available on github [https://github.com/eilslabs/
ACEseqWorkflow]. Briefly, ACEseq (allele-specific copy number estimation from
whole-genome sequencing) determines copy number states, tumor cell content,
ploidy, and sex in the tumor by using read coverage and the B-allele frequency
(BAF). Heterozygous germline positions (with BAF 0.33–0.77 at dbSNP version
135 SNP loci)65 are identified for later allele-specific copy number and loss-of-
heterozygosity (LOH) analysis. Phasing is performed using impute2 on hetero-
zygous and homozygous alternative SNP positions to improve sensitivity of
detection of imbalanced and balanced regions66. Tumor and control read coverage
is calculated for 10 kb windows with sufficient mapping quality and read density,
which is then corrected for GC-content and replication timing bias using linear
regression, removing coverage fluctuations associated with these biases. Genome
segmentation is performed using the PSCBS package in R additionally including
the previously identified SV breakpoints67. Small segments (<9 kb) are merged to
their most similar neighboring segment. Segments are c-means clustered according
to their coverage ratio and BAF. Neighboring segments are joined if they belong to
the same cluster. Sample ploidy and tumor cell content are estimated by scanning
different ploidy and purity combinations and selecting the ones that best described
the data. As a constraint, balanced BAF segments are fitted to even-numbered copy
number states but unbalanced BAF segments were additionally fitted to uneven
numbers. Then the allele-specific copy number for each segment is calculated using
the fitted estimated tumor cell content and ploidy.
For subsequent analysis, gains and losses were identified when they deviate
more than 0.7 from the base ploidy. Annotation of genes was based on direct
overlap with gene models from gencode version 19.
We observed recurrent chromosome arm-level changes, included gains 7p and
q, 8q, 13q, 19q, and 20p and q, and deletions in 1p, 4q, 8p, 15q, 17p, and 18q,
which have been described in the TCGA study5. In addition, we observed recurrent
amplifications of chromosome arms 6p and q and 16p and losses in 4p, 5q, 8p
(contrary to TCGA), and 18p and Y (in males). Chromosomes 8, 13, 18, and 20
were observed to have the most recurrent alterations. Six patients harbored CNAs
on all of these chromosomes.
Identification of kataegis loci. Kataegis loci were classified as clusters of a
minimum of 5 mutations within a 10 kb region. Annotation of genes to kataegis
loci was done using bedtools using the gencode version 19 gene models. A kataegis
locus was determined to be proximal to a gene if it was within 10 kb of it.
Supervised mutational signatures analysis. Supervised mutational signatures
analysis was performed using the R package YAPSA [https://rdrr.io/bioc/YAPSA/].
The linear combination decomposition of the mutational catalog with known and
predefined COSMIC signatures68 was computed by non-negative least squares
(NNLS) as described in Giessler et al.69. The mutational signature analysis was
applied to the mutational catalogs for SNVs of the 8 high-purity paired tumors and
metastasis samples individually and tumor-specific and metastasis-specific muta-
tions per patient. A signature-specific cutoff was applied and cohort level analysis
was used for detecting signatures.
Ingenuity pathway analysis. All genes hit by non-synonymous, including stop
gain SNVs and indels were imported into the core analysis pipeline of the Ingenuity
Pathway Analysis tool. Genes that were hit multiple times were included as an
individual entry. SNVs and indels were combined together and exonic mutations in
primary tumors (822 genes), metastasis (913 genes), primary tumor 3′-UTRs (770
genes) and metastasis 3′-UTRs (809 genes) were analyzed individually. Core
analysis was performed with the default settings and the most significant pathways
were selected after removal of those unrelated to cancer, GI disease or colorectal
physiology.
Annotation enrichment analysis with DAVID. All genes hit by metastasis-specific
mutations and indels that were mutated at least twice as much in metastasis
samples compared to tumors were imported into functional annotation clustering
tool of DAVID. The homo sapiens background, medium stringency and
Benjamini-Hochberg correction was applied to the hypergeometric test.
In silico evaluation of miRNA binding to mutated 3′-UTRs. All predictions were
made with the RNA22 interactive software [https://cm.jefferson.edu/rna22/
Interactive/] using all known miRNA (miR) sequences from miRBase (Release 21)
and the corresponding wild-type or mutated sequences as input. Default settings
were used with sensitivity at 63%, specificity at 61%, seed size of 7 with a maximum
of one unpaired base. The minimum number of paired-up bases in the hetero-
duplex was 12, the maximum folding energy for the heteroduplex (Kcal/mol) was
−515 and no limit was given on the number of potential GU wobbles in the seed
region. Gain- or loss-of-potential miRNA binding was evaluated by positive results
in the presence or absence of a given mutation.
Data availability
The whole-genome sequencing data have been deposited at the European Genome-
phenome Archive (EGA). The EGA Study Accession ID is EGAS00001002717. All
the other data supporting the findings of this study are available within the article
and its supplementary information files and from the corresponding author upon
reasonable request.
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